GLP-1 and ADHD: What Is and Isn't Known (October 2026)

01 · The short answer

Is GLP-1 treatment relevant if you have ADHD?

It is relevant only if you are considering a GLP-1 medicine for its licensed purpose, which is weight management or type 2 diabetes. It is not a treatment for inattention, hyperactivity or impulsivity. The Mounjaro product information describes weight management and type 2 diabetes as its uses, and ADHD is not among them.¹

Many adults with ADHD still ask about GLP-1 medicines. Some struggle with weight. Some describe constant thoughts about food. Some have read social media posts claiming a GLP-1 injection quietened their mind.

02 · Your decision

The decisions you are actually facing

• Could a GLP-1 treat my ADHD? No licensed GLP-1 medicine is indicated for that. If your ADHD symptoms are the problem, speak to your ADHD prescriber or GP.
• Can I take a GLP-1 alongside my ADHD medicine? That is a question for a prescriber who can see your full medicine list. See our guide to combining it with ADHD medication.
• Do I qualify for weight-loss treatment at all? Eligibility depends on your BMI and health, not on whether you have ADHD. Treatment is used alongside a reduced-calorie diet and increased physical activity.¹

03 · Next step

What to do next

Start with an honest list of everything you take, including your ADHD medicine, its brand and any other prescriptions or supplements. Then decide whether weight management is a goal you want to discuss with a prescriber. If it is, you can complete a free online consultation, which is reviewed by a GPhC-registered prescriber rather than a scoring script. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.

For broader background on treatment, our weight loss clinic hub explains how the service works.

Equally, if your main concern is ADHD itself, the right next step is not a weight-loss injection. It is a conversation with whoever manages your ADHD care.

04 · Reading the claims

How to read claims about GLP-1 and ADHD

Be cautious whenever a claim sounds like a cure. A reasonable test has three parts. Is the medicine licensed for that purpose? Is the claim attributed to a named trial or regulator document? Does the source say what the medicine did, or only what a few people felt? Claims about GLP-1 and ADHD usually fail all three tests. That does not mean research will never explore the area. It means that today, you should treat the idea as unproven and make decisions based on the licensed uses.

05 · What GLP-1 medicines are

What GLP-1 medicines are, and what they are licensed for

GLP-1 medicines copy or act on a natural gut hormone involved in appetite and blood sugar control. In the UK they are prescription-only and are licensed for specific purposes. Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine made by Eli Lilly. In the UK it is licensed for weight management in adults and for type 2 diabetes.¹ It comes as a pre-filled multi-dose pen (KwikPen) in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹

Wegovy, which contains semaglutide, belongs to the same wider family and is also a once-weekly injection for weight management. Its pens run through a ladder of 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg, with the dose stepping up after at least four weeks and the 2.4mg dose being the licensed maintenance dose.¹⁸ Liraglutide, found in Saxenda, is a daily injection supplied at a concentration of 6mg/ml. Each of these has its own licensed purpose and its own product information.

None of these licences includes ADHD. A licence is not a technicality. It reflects the conditions for which a manufacturer has submitted trial data and a regulator has judged the balance of benefit and risk acceptable. A medicine used for something outside its licence is not necessarily dangerous, but it lacks that formal backing, and we do not promote it.

Why does this matter for someone with ADHD? Because the phrase "GLP-1 for ADHD" suggests a treatment relationship that does not exist in the regulatory sense. If you see it in an advert, a forum post or a video, read it as a topic of discussion rather than an approved use. Our guidance elsewhere on GLP-1 agonists explains the drug class in more depth.

It also matters because of how we treat your health information. When you complete a consultation with us, the prescriber is deciding whether Mounjaro is suitable for weight management in your circumstances. They are not deciding whether it will treat ADHD, and they should not be asked to. Being clear about the purpose keeps the conversation useful and keeps expectations realistic.

Finally, remember that Mounjaro is used alongside a reduced-calorie diet and increased physical activity. It is not a substitute for them.¹ Treatment is also a prescription decision, supplied only after an online consultation reviewed by a GPhC-registered prescriber. That applies equally whether or not you have ADHD.

06 · Why the link gets discussed

Why people connect GLP-1 medicines with ADHD

The connection comes mostly from lived experience and online conversation, not from trial evidence. Many adults with ADHD describe a difficult relationship with food: eating impulsively, grazing, or finding it hard to stop thinking about the next meal. When some of them start a GLP-1 medicine and feel less preoccupied with eating, they naturally wonder whether something broader is happening in the brain.

Mounjaro activates two natural gut-hormone receptors, GIP and GLP-1, which together help regulate appetite, slow how quickly the stomach empties and improve the way the body responds to insulin. In practice, most people feel fuller sooner and less hungry between meals.¹ That is an appetite effect, and it can feel like a quieter relationship with food. It is not the same as a documented effect on attention, executive function or hyperactivity.

Why does the idea spread so easily? Several reasons are worth naming:

• People notice real changes in appetite and describe them in broad language such as "calmer" or "more in control".
• Stories travel faster than trial data, particularly on social platforms.
• ADHD affects daily functioning, so any perceived benefit feels significant.
• Weight change itself can improve mood, energy and confidence, which people sometimes attribute to something more specific.

None of that makes anyone's experience untrue. It means one person's experience cannot tell you what a medicine does for people in general. That is why trials exist, and why licensed uses are the safest foundation for a decision.

If you are curious about the topic, our page on trapezoid GLP-1 questions and the related piece on AMPK and GLP-1 look at other corners of the science that readers ask about.

The practical takeaway is simple. If less food preoccupation is something you want help with, that is a legitimate reason to discuss weight management with a prescriber. If treating ADHD is your goal, a GLP-1 is not the tool, and you should talk to your ADHD clinician.

07 · What the evidence shows

What the evidence does and does not show

None of the licensed uses or named trials of these medicines examine ADHD outcomes.

Consider the weight-loss evidence for Mounjaro. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone. These are trial averages, and individual results vary.² That finding concerns body weight. It says nothing about attention or impulsivity, and it should not be stretched to cover them.

It is also worth separating three kinds of information that often get blurred together:

• Trial evidence from a defined group of people, measured against a comparison group, published in a journal.
• Regulatory product information that sets out the licensed use, dosing and safety warnings.
• Personal reports from social media, forums and conversations, which are not evidence of effect.

Most GLP-1 and ADHD discussion sits in the third category. That is not a criticism of the people sharing. It is simply what the material is. When you read a headline implying that a weight-loss injection treats ADHD, ask which of the three categories it comes from.

What should you do if your doctor says they do not have a direct answer on GLP-1 and ADHD interactions? That is an honest response. It usually means there is no specific guidance beyond the general product information and a sensible review of your medicines. A prescriber can still weigh your overall health, your current prescriptions and your goals.

We would also caution against the opposite error. Absence of evidence for ADHD benefit does not mean having ADHD makes Mounjaro unsafe or unsuitable. It means the question needs an individual assessment, which is exactly what the consultation provides. The product information and patient leaflet remain the reference for side effects and precautions.¹³

If you want a deeper walk-through of this specific question, see does GLP-1 help ADHD, which expands on how to read the claims.

08 · Appetite and food noise

Appetite, food noise and impulsive eating

Mounjaro's documented effect is on appetite, and that is the part of the GLP-1 and ADHD conversation with a real basis. Tirzepatide helps regulate appetite and slows how quickly the stomach empties, and in practice most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.¹ If constant thoughts about food are part of your struggle, that appetite effect may be why you notice a difference.

"Food noise" is a popular term rather than a clinical one. People use it to describe persistent thinking about eating.

Is that the same as better impulse control? Not necessarily. Eating less often is an appetite outcome. ADHD-related impulsivity covers many situations, including spending, interrupting and acting without thinking. A medicine that makes you feel full does not address those, and you should not expect it to.

Some practical points for people who recognise impulsive eating:

• Treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.¹
• Routine can help. Weekly injections suit many people with ADHD because the schedule is simple, though you still need a reliable reminder. The free GLPTrackr app can help you track your journey.
• Tell your prescriber about disordered eating patterns, since they affect whether treatment is appropriate.
• Report any new or worsening symptoms to your prescriber. For severe, persistent stomach pain, chest pain, fainting, swelling of the face, lips, tongue or throat, or difficulty breathing, get medical help straight away.

It is also fair to say that people with ADHD may find some parts of a weight-loss plan harder, such as meal planning or remembering to eat enough. A prescriber and the ongoing monthly reviews we include can help you adjust. Aftercare includes dose titration, follow-up assessments and side-effect support.

Finally, avoid judging treatment by whether it fixes everything. If your appetite settles and you eat more calmly, that is a meaningful outcome in itself. If your ADHD symptoms remain, that is not a failure of the injection. It is a reminder that those symptoms need their own plan, discussed with the clinician who manages your ADHD.

09 · Taking Mounjaro with ADHD

Taking Mounjaro if you have ADHD

Having ADHD does not automatically stop you being considered for Mounjaro, but your prescriber needs the full picture before deciding. The decision rests on the licensed criteria for weight management, your general health and everything else you take. That is why we ask for a complete medicines history in the consultation rather than treating it as a formality.

Be specific when you describe your treatment. Include the name of your ADHD medicine, whether it is a stimulant or non-stimulant, how long you have taken it and who prescribes it. Mention any other regular medicines too. Our consultation is free, and the short health questionnaire carries no obligation. A GPhC-registered prescriber reviews it, and unsuitable orders are refunded automatically.

Does Mounjaro interact with ADHD medicines? The patient leaflet and product information are the reference for interactions, and your prescriber can interpret them for you.¹³ One general point the product information does make is that Mounjaro slows how quickly the stomach empties, and for oral contraceptives this can reduce absorption.¹ The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.¹ Tell your prescriber about every oral medicine so they can consider whether anything else needs attention.

For more on combinations, our guide to taking GLP-1 with ADHD meds sets out questions to ask. Our page on Mounjaro and ADHD covers the product-specific angle.

Some sensible habits if you go ahead:

• Do not change, skip or stop your ADHD medicine on your own because you are starting something new.
• Keep your ADHD prescriber informed, and ask whether they want to review you after a dose change.
• Note any changes in sleep, mood, appetite or focus, and report them at your monthly review rather than waiting.
• Use the Yellow Card scheme to report suspected side effects, since reports help regulators monitor safety.¹⁹

If you notice something that is not on the leaflet's list of side effects, tell your prescriber about any new or lasting symptom. You can also report suspected side effects through the MHRA Yellow Card scheme.

Finally, repeat orders re-check suitability, and there is no auto-shipping. So if your circumstances change, for example you start a new ADHD medicine, the next review is where to say so.

10 · ADHD medicines and weight

ADHD medicines, appetite and weight

Your ADHD medicine may itself influence appetite or weight, and the leaflet for that medicine is the place to check.

This matters when you are thinking about a GLP-1 medicine. If your appetite is already affected by your ADHD treatment, adding another appetite-affecting medicine is something a prescriber will want to consider carefully. Likewise, if you have recently changed your ADHD medicine, the timing of any new treatment is worth discussing. Our page on ADHD drugs and weight loss goes further into this relationship.

Several of the questions people ask in this area are about ADHD medicines themselves, including withdrawal symptoms, downsides and what you cannot do while taking them.

• Read the patient information leaflet for your specific ADHD medicine.
• Do not stop an ADHD medicine abruptly without speaking to the prescriber who manages it.
• If a symptom worries you, contact your prescriber or GP. For chest pain, fainting, a racing heart or difficulty breathing, get medical help straight away.
• Report suspected side effects through the Yellow Card scheme.¹⁹

What about weight gain or loss for reasons unrelated to either medicine? Sleep, stress, routine and mood all affect eating. Many adults with ADHD find routine hard to maintain, which can make weight harder to manage regardless of treatment. A GLP-1 medicine, used for its licensed purpose and alongside diet and activity, is one possible tool. It does not replace attention to the basics.

If you are weighing up your options, a good approach is to write a short note listing your ADHD medicine, your weight-related goals and your questions, then bring it to a prescriber. That keeps the conversation structured, which many people with ADHD find easier than relying on memory on the day.

11 · NHS, private and expected results

NHS access, private treatment and realistic results

Mounjaro is available on the NHS, but access is being phased in over several years.⁶ NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

Having ADHD is not a listed route onto the NHS pathway or an exclusion from it. Your eligibility turns on weight, related conditions and local arrangements, and your GP is the person to ask. Wegovy access on the NHS runs through specialist weight-management services, so ask your GP about that too.

If you choose private treatment, the service is a GPhC-registered pharmacy, registration GPhC 9012878, and Mounjaro is supplied through official LillyDirect supply, sourced directly from Eli Lilly. The consultation is free, and the price shown is the price paid with no hidden fees.

What results can you expect? In SURMOUNT-1, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone. These are trial averages, individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.² As a worked example, for someone starting at 100 kg, 20.9% is about 21 kg.

None of these figures relate to ADHD. They describe weight change only.

Delivery is free next-day tracked delivery in temperature-controlled packaging, with same-day dispatch when ordered by 3pm. Needles, a sharps bin and injection guidance are included with every order. Support is available Monday to Friday, 9am to 5pm.

12 · Safety, storage and stopping

Safety, storage and what happens if you stop

Mounjaro is a prescription-only medicine, supplied only after an online consultation reviewed by a GPhC-registered prescriber, and it carries side effects and precautions listed in the patient leaflet. Read that leaflet before you start, and keep it. If you have ADHD, pay particular attention to the section on other medicines and to any warnings about mood or eating behaviours, then raise questions with your prescriber.¹³

Reporting matters. If you experience something unexpected, you can report it through the MHRA Yellow Card scheme, which helps regulators monitor medicines after they reach the market.¹⁹

Storage is straightforward, but it is easy to forget if your routine is busy. Keep unopened pens in the fridge at 2–8°C until first use. They keep until the printed expiry date. Once you start using a pen, it can be kept out of the fridge at a temperature not above 30°C for up to 30 days after first use, and must then be thrown away. Do not use a pen that has been above 30°C or frozen. For anything else about storage, check the patient information leaflet or ask the pharmacy.¹³

What if you decide to stop? Tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system. There is no way to speed this up, and nothing needs doing while it clears.¹ Mounjaro manages weight; it does not cure the biology behind it. In SURMOUNT-4, people who stopped tirzepatide after 36 weeks regained on average 14% of body weight over the following year, while those who continued treatment lost a further 5.5% on average. Stopping should always be planned with your prescriber, with diet and activity habits ready to carry the load. If you also take an ADHD medicine, do not change it simply because you are stopping or starting an injection. Speak to the prescriber who manages it.

A few safety habits are worth building in, especially if routine is a challenge:

• Set a recurring weekly reminder for the injection day.
• Keep your pens, needles and sharps bin together in a consistent place.
• Follow the pen's instructions for each injection rather than relying on memory.
• Only buy from a registered pharmacy. Counterfeit medicine alerts are issued by the MHRA, and anyone offering to supply without a consultation or prescription should be avoided.⁷

You can check our registration yourself on the GPhC register: GPhC 9012878.¹² That is a simple step, and it is worth doing with any online pharmacy.

Mounjaro is used alongside a reduced-calorie diet and increased physical activity, and individual results vary.¹ If you are unsure whether it suits you, the consultation is the right place to ask, and it is free.

13 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹